ITM Isotope Technologies Munich SE (ITM), the Technical University of Munich (TUM), and the TUM University Hospital have reached an agreement for the research and development of radiopharmaceuticals and radionuclides for cancer treatment.
The new agreement aims to further accelerate nuclear medicine initiatives by integrating ITM’s expertise with TUM’s research capabilities in nuclear physics and medical applications, alongside the hospital's clinical expertise in diagnostics and patient care. It also outlines how ITM and TUM will share and transfer the rights to any results or inventions that come from the collaboration.
Company and institutional leaders met in late September to formalize and sign the agreement, as well as tour ITM’s NOVA lutetium-177 production site in Neufahrn.
Since its founding in 2004, ITM and the TUM have forged a partnership that has contributed to the development of ITM’s non-carrier-added lutetium-177 and helped pave the way for ITM to establish its NOVA facility. ITM and its IAZ manufacturing facility are headquartered on the TUM’s Garching campus.
